Operating profit before amortization: grail.com (GRAL)

Public company logo of GRAIL (GRAL)

The success of GRAIL, Inc. (GRAL) relies on Medicare approval and test accuracy, while a seamless express delivery network for biomaterials ensures process stability. The trend in gross operating profit before depreciation confirms these points, where 0.00 characterizes this valuation parameter. Since demand for cancer screening is independent of macroeconomic conditions, business growth is driven solely by the pace of physician technology adoption.

GRAL GRAIL Bio: Profit before payment of interest, taxes and amortization in the range 11/23/2025 - 11/10/2026

Summary analytical data breakdowns for GRAIL (GRAL)

- market price and analyst price targets:
Stock Price GRAIL Bio|GRAL - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization GRAIL|GRAL - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share GRAIL|GRAL - Company Book Value|Market Value to Book Value Ratio grail.com|GRAL - Cumulative Company Assets
- business debt structure and liquidity details:
Debt to Capital GRAIL, Inc.|GRAL - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient GRAIL Inc|GRAL - Company Aggregate Debts|Debts to Net Assets GRAIL|GRAL - Company Long-Term Debt|Short-Term Debt Volume GRAIL|Critical Liquidity grail.com
- business earnings and investment ratios data:
GRAL - Company Net Income|Expected Net Income GRAIL, Inc.|GRAL - P/E Multiple|Forward P/E Multiple grail.com|GRAL - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio GRAIL|GRAL - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months GRAIL|GRAL - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months grail.com|GRAL - Earnings growth in current year|Consensus forecast of earnings per share growth for next year GRAIL, Inc.
Summary company analytics:GRAL GRAIL Bio
Manufactured product of GRAIL Corp

The efficiency of developing innovative cancer tests at GRAIL, Inc. (GRAL) correlates directly with the volume of cash flow generated from core operations. This metric excludes the impact of depreciation and debt service, capturing the actual inflow of liquidity. By analyzing absolute EBITDA, investors can discern the market consensus regarding the value of the bioinformatics team's intellectual labor. Sharp fluctuations in absolute EBITDA may mask systemic risks as temporary undervaluation, whereas steady growth in this indicator confirms the resilience of the business model.

Competitors of GRAIL, Inc. (GRAL)

Operating profit EBITDA Caris Corp CAI|GH - Profit before payment of interest, taxes and amortization|VCYT (veracyte.com) - Operating profit before amortization|CELC: Operating profit EBITDA|Myriad Genetics Inc (MYGN) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Castle Biosciences Corp|Profit before payment of interest, taxes and amortization BNR|Operating profit before deduction of amortization VNRX (VolitionRx Limited)|BDSX - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Precipio PRPO|Operating income before deduction of amortization Check-Cap Ltd (CHEK)|Mainz Biomed - Operating profit EBITDA|Operating income before deduction of amortization OncoCyte Inc OCX